<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02912325</url>
  </required_header>
  <id_info>
    <org_study_id>OPMDM/0216/FS</org_study_id>
    <nct_id>NCT02912325</nct_id>
  </id_info>
  <brief_title>Non-Comparative Study to Assess the Efficacy and Safety of the New Food Supplement FaseMETS</brief_title>
  <official_title>A Pilot, Non-Comparative Study to Assess the Efficacy and Safety of the New Food Supplement FaseMETS in Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MDM S.p.A.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Opera Contract Research Organization SRL</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>MDM S.p.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to evaluate the efficacy of FaseMETS for 6 consecutive months in
      lowering serum lipids and glucose in subjects with Metabolic Syndrome;

      The secondary objectives of the trial are:

        -  to evaluate the potential benefit after 3 months of therapy (by an interim analysis)

        -  to evaluate the safety of FaseMETS
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial is designed as a multicenter, open label, non-comparative, 6 months, pilot study.

      The primary objective is to evaluate the efficacy of FaseMetS ® administered for 6 months
      treatment combined with a health management plan in reducing the serum lipidemic profile
      (this includes total cholesterol, LDL cholesterol, HDL cholesterol, small density LDL
      particles, triglycerides, serum glucose, glycated haemoglobin (HBA1c), insulin, and
      pro-insulin, HOMA index, uric acid, body mass index (BMI), creatine phosphokinase) in
      patients diagnosed with Metabolic Syndrome and with mild to moderate Hypercholesterolemia.

      The secondary objectives are:

        -  to evaluate the efficacy in reducing the serum lipidemic profile after a period of 3
           months of FaseMetS ® ® treatment;

        -  to evaluate the safety of FaseMetS ® treatment by recording AE/SAE (with particular
           regards for gastrointestinal symptoms);

        -  improvement of blood clinical laboratory parameters;

        -  improvement of weight control systolic blood pressure and diastolic blood pressure
           control
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2017</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Actual">October 15, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum lipidemic profile evaluated at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>laboratory test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum lipidemic profile evaluated at 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>laboratory test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE/SAE (with particular regards for gastrointestinal symptoms)</measure>
    <time_frame>6 months</time_frame>
    <description>blood clinical laboratory parameters
physical examination including weight, systolic blood pressure and diastolic blood pressure</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>FaseMetS ® a food supplement</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Daily administration: 2 tablets FaseMETS a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Daily administration: 2 tablets FaseMETS a day</intervention_name>
    <description>Treatment with FaseMETS for 6 consecutive months in lowering serum lipids and glucose in subjects with Metabolic Syndrome</description>
    <arm_group_label>FaseMetS ® a food supplement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  men or women

          -  age &gt; 45 and ≤70 years

          -  on cardiovascular disease prevention in clinical practice

          -  written informed consent.

          -  total cholesterol≥240 mg/dL

          -  diagnosis of metabolic syndrome with three or more of the following:

               -  Waist circumference: ≥89 cm for women and ≥102 cm for men or BMI≥30 Kg/m2;

               -  Triglycerides level: ≥ 175 mg/dL or 1.7 mmol/L

               -  HDL &lt;40 mg/dL (1.04 mmol/L) in men or &lt;50 mg/dL (1.3 mmol/L) in women

               -  Blood sugar (fasting plasma glucose): ≥120 mg/dL (6.7 mmol/L)

        Exclusion Criteria:

          -  Pregnancy or lactation;

          -  Patients at very high or low cardiovascular risk, having a calculated SCORE ≥10% or
             &lt;1% respectively

          -  History of atrial fibrillation or atrial flutter

          -  Patient in treatment with indication to oral anticoagulants or other antithrombotic
             drugs

          -  Patients with severe gastro-intestinal tract disorders with possible influence on drug
             absorption or electrolytes.

          -  Patients with myeloproliferative disorders

          -  Patients with severe chronic kidney disease (GFR 30 mL/min/ 1.73 m2), using
             Cockcroft's formula, with known liver disease or biliary obstructive disorders,
             chronic hepatitis, cirrhosis, with hyperkalemia or with ALAT or ASAT upper than 3
             times the upper limit of normal laboratory range.

          -  History of alcoholism or drug abuse.

          -  Uncontrolled dysthyroidism, Cushing's syndrome, acromegalia, hyperparathyroidism.

          -  Patients with HIV or taking drugs for HIV.

          -  Patients taking statins or other dyslipidemic /hypolipidemic agents (drugs, food
             supplements, etc).

          -  Patients taking antidiabetic drugs (i.e metformin, acarbose and/or others).

          -  Patients unlikely to co-operate in the study or to comply well with treatment or with
             the study visits.

          -  Participation in another study at the same time or within the preceding 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Maggi, MD</last_name>
    <role>Study Director</role>
    <affiliation>MDM SpA Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dionisio Barattini, MD</last_name>
    <phone>+393355437574</phone>
    <email>barattini@operacro.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Serban Rosu, MD</last_name>
    <email>rosu@operacro.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Opera Contract Research Organization SRL</name>
      <address>
        <city>Timisoara</city>
        <state>Timis</state>
        <zip>300209</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barattini Dionisio, MD</last_name>
      <phone>+393355437574</phone>
      <email>barattini@operacro.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Scm Dr Rosu</name>
      <address>
        <city>Timişoara</city>
        <state>Timis</state>
        <zip>300209</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doina Rosu, MD</last_name>
      <email>dr_doinarosu@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Romania</country>
  </location_countries>
  <reference>
    <citation>Gielen S, Sandri M, Schuler G, Teupser D. Risk factor management: antiatherogenic therapies. Eur J Cardiovasc Prev Rehabil. 2009 Aug;16 Suppl 2:S29-36. doi: 10.1097/01.hjr.0000359233.58023.64. Review.</citation>
    <PMID>19675434</PMID>
  </reference>
  <reference>
    <citation>Lorenzo C, Wagenknecht LE, D'Agostino RB Jr, Rewers MJ, Karter AJ, Haffner SM. Insulin resistance, beta-cell dysfunction, and conversion to type 2 diabetes in a multiethnic population: the Insulin Resistance Atherosclerosis Study. Diabetes Care. 2010 Jan;33(1):67-72. doi: 10.2337/dc09-1115. Epub 2009 Oct 6.</citation>
    <PMID>19808919</PMID>
  </reference>
  <reference>
    <citation>Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005 Oct 8;366(9493):1267-78. Epub 2005 Sep 27. Erratum in: Lancet. 2005 Oct 15-21;366(9494):1358. Lancet. 2008 Jun 21;371(9630):2084.</citation>
    <PMID>16214597</PMID>
  </reference>
  <reference>
    <citation>Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006 Aug 1;48(3):438-45. Epub 2006 Jul 12.</citation>
    <PMID>16875966</PMID>
  </reference>
  <reference>
    <citation>Alsheikh-Ali AA, Karas RH. The relationship of statins to rhabdomyolysis, malignancy, and hepatic toxicity: evidence from clinical trials. Curr Atheroscler Rep. 2009 Mar;11(2):100-4. Review.</citation>
    <PMID>19228482</PMID>
  </reference>
  <reference>
    <citation>Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med. 2009 Jun 16;150(12):858-68. Review.</citation>
    <PMID>19528564</PMID>
  </reference>
  <reference>
    <citation>Rondanelli M, Giacosa A, Orsini F, Opizzi A, Villani S. Appetite control and glycaemia reduction in overweight subjects treated with a combination of two highly standardized extracts from Phaseolus vulgaris and Cynara scolymus. Phytother Res. 2011 Sep;25(9):1275-82. doi: 10.1002/ptr.3425. Epub 2011 Feb 10.</citation>
    <PMID>21308825</PMID>
  </reference>
  <reference>
    <citation>Luzzi R, Belcaro G, Hu S, Dugall M, Hosoi M, Ippolito E, Corsi M, Gizzi G. Beanblock® (standardized dry extract of Phaseolus vulgaris) in mildly overweight subjects: a pilot study. Eur Rev Med Pharmacol Sci. 2014 Oct;18(20):3120-5.</citation>
    <PMID>25392114</PMID>
  </reference>
  <reference>
    <citation>Bunnoy A, Saenphet K, Lumyong S, Saenphet S, Chomdej S. Monascus purpureus-fermented Thai glutinous rice reduces blood and hepatic cholesterol and hepatic steatosis concentrations in diet-induced hypercholesterolemic rats. BMC Complement Altern Med. 2015 Mar 28;15:88. doi: 10.1186/s12906-015-0624-5.</citation>
    <PMID>25880551</PMID>
  </reference>
  <reference>
    <citation>Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985 Jul;28(7):412-9.</citation>
    <PMID>3899825</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2016</study_first_submitted>
  <study_first_submitted_qc>September 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2016</study_first_posted>
  <last_update_submitted>January 12, 2018</last_update_submitted>
  <last_update_submitted_qc>January 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

